Washington University registers phase 3 trial of somatostatin analogues after PRRT
The REMAIN trial randomizes patients with nonfunctional neuroendocrine neoplasms to continued somatostatin analogue therapy or observation after Lu-177 dotatate.
PR
By Priya Raman · Science Reporter
Oct 19 08:00 ETSource: ClinicalTrials.gov
The wire
- 01NCT07842172 is a multicenter, randomized, open-label phase 3 study comparing standard-of-care somatostatin analogues with observation following peptide receptor radionuclide therapy using ethanol-stabilized Lu-177 dotatate, starting 30 November 2026.
- 02The question of whether to continue octreotide-class therapy after PRRT is a routine clinical decision with little randomized evidence behind it.
- 03The trial is not yet recruiting and is sponsored by Washington University School of Medicine; no endpoints or enrollment target were listed in the registration summary.
From the source
Read at clinicaltrials.govSomatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
NCT07842172 · PHASE3 · NOT YET RECRUITING · Sponsor: Washington University School of Medicine · Conditions: Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm.
Source URL https://clinicaltrials.gov/study/NCT07842172
